Side‑ effects of Modern Immunotherapy and How to Solve Them in the Clinics

Česká verzia

Authors: R. Lakomý; A. Poprach
Authors place of work: Klinika komplexní onkologické péče LF MU a Masarykův onkologický ústav, Brno
Published in the journal: Klin Onkol 2015; 28(Supplementum 4): 103-114
Category: Specials
doi: https://doi.org/10.14735/amko20154S103

Oba autoři se na práci podíleli stejným dílem.

Summary

Background:
The standard treatment of advanced melanoma has been changing in recent years. Palliative chemotherapy is being replaced by more efficient targeted therapies and modern immunotherapies based on antibodies against checkpoints of the immune response (so‑ called checkpoint inhibitors). Today‘s standard ipilimumab (anti‑CTLA‑ 4 antibody) could significantly prolong overall survival and achieved long‑term disease control in about 20% of patients. There are other perspective immune modulating agents, such as anti‑PD‑ 1 antibodies (nivolumab, pembrolizumab, pidilizumab) and anti‑PD‑ L1 antibodies. Unique mechanism of action is accompanied by new types of immune‑related adverse events.

Aim:
The aim of the article is to summarize current knowledge about the toxicity of these antibodies and propose solutions in routine clinical practice.

Key words:
melanoma – immunotherapy – ipilimumab – toxicity

This study was supported by MZ CZ – RVO (MMCI, 00209805).

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
23. 6. 2015

Accepted:
31. 7. 2015

Zdroje

1. Hodi FS, O‘Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8): 711– 723. doi: 10.1056/ NEJMoa1003466.

2. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364(26): 2517– 2526. doi: 10.1056/ NEJMoa1104621.

3. Weber JS, D‘Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti‑CTLA‑ 4 treatment (CheckMate 037): a randomised, controlled, open‑ label, phase 3 trial. Lancet Oncol 2015; 16(4): 375– 384. doi: 10.1016/ S1470‑ 2045(15)70076‑ 8.

4. Robert C, Long GV, Brady B el al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372(4): 320– 330. doi: 10.1056/ NEJMoa1412082.

5. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369(2): 122– 133. doi: 10.1056/ NEJMoa1302369.

6. Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti‑PD‑ 1) in melanoma. N Engl J Med 2013; 369(2): 134– 144. doi: 10.1056/ NEJMoa1305133.

7. Robert C, Ribas A, Wolchok JD et al. Anti‑programmed‑ death‑ receptor‑ 1 treatment with pembrolizumab in ipilimumab‑ refractory advanced melanoma: a randomized dose‑comparison cohort of a phase 1 trial. Lancet 2014; 384(9948): 1109– 1117. doi: 10.1016/ S0140‑ 6736(14)60958‑ 2.

8. Cancer.gov [homepage on the Internet]. New York: National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v4.0; c2014 [updated 2014 March 25; cited 2015 May 5]. Available from: http:/ / ctep.cancer.gov/ protocolDevelopment/ electronic_applications/ ctc.htm#ctc_40.

9. Fecher LA, Agarwala SS, Hodi FS et al. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013; 18(6): 733– 743. doi: 10.1634/ theoncologist.2012‑ 0483.

10. Wolchok JD, Neyns B, Linette G et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomized, double‑blind, multicentre, phase 2, dose‑ranging study. Lancet Oncol 2010; 11(2): 155– 164. doi: 10.1016/ S1470‑ 2045(09)70334‑ 1.

11. Weber JS, Kahler KC, Hauschild A. Management of immune‑related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30(21): 2691– 2697. doi: 10.1200/ JCO.2012.41.6750.

12. Schmerling RA. Toxicity of checkpoint inhibitors. Chin Clin Oncol 2014; 3(3): 31. doi: 10.3978/ j.issn.2304‑ 3865.2014.08.03.

13. Sukl.cz [homepage on the Internet]. State institue for drug controll.Summary of product characteristics Yervoy; c2012 [updated 2012 March 15; cited 2015 May 5].Available from: http:/ / www.ema.europa.eu/ docs/ cs_CZ/ document_library/ EPAR_– _Product_Information/ human/ 002213/ WC500109299.pdf.

14. Weber J, Thompson JA, Hamid O et al. A randomized, double‑blind, placebo‑ controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009; 15(17): 5591– 5598. doi: 10.1158/ 1078‑ 0432.CCR‑ 09‑ 1024.

15. Harmankaya K, Erasim C, Koelblinger C et al. Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol 2011; 28(4): 1140– 1144. doi: 10.1007/ s12032‑ 010‑ 9606‑ 0.

16. Della Vittoria Scarpatti G, Fusciello C, Perri F at al. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets Ther 2014; 7: 203– 209. doi: 10.2147/ OTT.S57335.

17. O‘Day SJ, Maio M, Chiarion‑ Sileni V et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single‑arm phase II study. Ann Oncol 2010; 21(8): 1712– 1717. doi: 10.1093/ annonc/ mdq013.

18. Lemech C, Arkenau HT. Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol 2012; 6: 53– 66. doi: 10.4137/ CMO.S5855.

19. Wilgenhof S, Neyns B. Anti‑CTLA‑ 4 antibody‑induced Guillain‑Barré syndrome in a melanoma patient. Ann Oncol 2011; 22(4): 991– 993. doi: 10.1093/ annonc/ mdr028.

20. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti‑PD‑ 1 antibody in cancer. N Engl J Med 2012; 366(26): 2443– 2454. doi: 10.1056/ NEJMoa1200690.

21. Langer CJ. Emerging immunotherapies in the treatment of non‑small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. Am J Clin Oncol 2015; 38(4): 422– 430. doi: 10.1097/ COC.0000000000000059.

22. Baurain JF, Smylie M, Ascierto PA et al. Outcomes of ipilimumab treatment‑related adverse events in patients with metastatic melanoma (MM) who received systemic corticosteroids in a phase III trial. J Clin Oncol 2012; 30 (Suppl): abstr. 8539.

23. Wolchok JD, Chiarion‑ Sileni V, Gonzalez R et al. Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment‑ naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). J Clin Oncol 2015; 33 (Suppl): abstr. LBA1.

24. Kyi C, Carvajal RD, Wolchok JD et al. Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer 2014; 2(1): 35. doi: 10.1186/ s40425‑ 014‑ 0035‑ z.

25. Lipson EJ, Bodell MA, Kraus ES et al. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol 2014; 32(19): e69– e71. doi: 10.1200/ JCO.2013.49.2314.

26. Ravi S, Spencer K, Ruisi M et al. Ipilimumab administration for advanced melanoma in patients with pre‑existing Hepatitis B or C infection: a multicenter, retrospective case series. J Immunother Cancer 2014; 2(1): 33. doi: 10.1186/ s40425‑ 014‑ 0033‑ 1.

27. Sharma A, Thompson JA, Repaka A et al. Ipilimumab administration in patients with advanced melanoma and hepatitis B and C. J Clin Oncol 2013; 31(21): e370– e372. doi: 10.1200/ JCO.2012.47.1946.

28. Kopecký J, Kubeček O, Trojanová P et al. Adverse effects of modern treatment of malignant melanoma and their treatment/ management. Klin Onkol 2014; 27(6): 393– 400. doi: 10.14735/ amko2014393.

29. Kopecký J, Trojanová P, Kubeček O et al. Treatment possibilities of ipilimumab‑induced thrombocytopenia – case study and literature review. Jpn J Clin Oncol 2015; 45(4): 381– 384. doi: 10.1093/ jjco/ hyu222.

30. Weber JS, Yang JC, Atkins MB et al. Toxicities of immunotherapy for the practitioner. J Clin Oncol 2015; 33(18): 2092– 2099. doi: 10.1200/JCO.2014.60.0379.